Viking Thera (VKTX) Stock Price, Quote & News

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selectiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4660

Website: www.vikingtherapeutics.com

Address:

9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

justaguy2u Mar. 7 at 8:07 AM

$VKTX Moscow in flames, missiles headed toward New York, film at 11. Stock is up, who cares.

0 · Reply

ProfessionalIntellige Mar. 7 at 4:46 AM

$VKTX biotech developments gaining attention

0 · Reply

chuckieclam Mar. 7 at 2:27 AM

$VKTX FYI - Bloomberg posted this. Not sure if it’s true. “Novo and Hims End Feud, Will Sell Obesity Drugs Together (3) March 6, 2026, 8:48 PM EST Madison Muller Madison Muller Email Madison Muller Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month. Novo and Hims plan to announce a new partnership as soon as Monday, according to the person, who spoke on the condition of anonymity. The two companies had a similar agreement last year, but Novo abruptly scrapped it after Hims refused to stop marketing and selling copycat medications.

1 · Reply

biolover Mar. 7 at 2:09 AM

$VKTX nothing surprising and irrelevant. Two failed companies.

2 · Reply

longshort00 Mar. 7 at 1:57 AM

$VKTX

1 · Reply

bavariaron Mar. 7 at 1:55 AM

$VKTX ** NVO and HIMS Partnership ** NVO and Hims bury the hatchet— Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports https://www.reuters.com/business/healthcare-pharmaceuticals/novo-hims-resolve-dispute-will-sell-obesity-drugs-together-bloomberg-news-2026-03-07/ VKTX Long-Term

0 · Reply

8BALLIAM Mar. 7 at 1:22 AM

$VKTX shorts will attack on Monday Novo removed as potential buyer so.. fml

4 · Reply

Mjstockwit Mar. 7 at 1:14 AM

$VKTX soooooo also do the Feds just drop the investigation into the compounders now and false claims?

0 · Reply

Mjstockwit Mar. 7 at 1:08 AM

$VKTX NVO running scared - they could’ve owned HIMS through the lawsuit but they panicked! Why?

1 · Reply

ElonMusk101 Mar. 7 at 12:47 AM

$HIMS $NVO $SRPT $VKTX all on the move!!! Own all 4!!! Wow!! LFG!!

0 · Reply

Viking Therapeutics to Participate at Upcoming Investor Conferences

Feb 23, 2026, 2:29 PM EST - 11 days ago

Viking Therapeutics Stock Gains Amid Obesity Drug Buzz

Feb 14, 2026, 8:44 AM EST - 20 days ago

Viking Therapeutics: Full-Speed Ahead

Feb 13, 2026, 8:35 AM EST - 21 days ago

Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential

Feb 12, 2026, 12:44 AM EST - 23 days ago

Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 5:10 PM EST - 23 days ago

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Feb 11, 2026, 4:33 PM EST - 23 days ago

Viking Therapeutics Stock Climbs After Q4 Report: Details

Feb 11, 2026, 4:16 PM EST - 23 days ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Feb 5, 2026, 6:03 PM EST - 4 weeks ago

The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short

Feb 4, 2026, 4:05 PM EST - 4 weeks ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Feb 3, 2026, 1:27 PM EST - 4 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO PFE

Jan 13, 2026, 1:35 AM EST - 7 weeks ago

Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:19 PM EST - 7 weeks ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 7:00 AM EST - 7 weeks ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 8, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 7, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 5, 2026, 4:03 PM EST - 2 months ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 10:57 AM EST - 2 months ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Jan 3, 2026, 10:00 AM EST - 2 months ago

Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over

Jan 1, 2026, 2:13 AM EST - 2 months ago

Viking Therapeutics: A Wide-Open Oral GLP-1 Market

Dec 28, 2025, 9:40 AM EST - 2 months ago

Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain

Dec 6, 2025, 8:57 AM EST - 3 months ago

Viking Therapeutics: Prepping For A Critical 2026

Nov 25, 2025, 4:05 PM EST - 3 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 1:58 PM EST - 3 months ago

3 Weight-Loss Drug Stocks To Consider For 2026

LLY NVO

Nov 19, 2025, 4:48 AM EST - 3 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 2:55 AM EST - 3 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 6, 2025, 7:05 AM EST - 4 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Nov 5, 2025, 10:01 AM EST - 4 months ago

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Oct 29, 2025, 4:05 PM EDT - 4 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 23, 2025, 10:42 AM EDT - 4 months ago

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Oct 23, 2025, 10:05 AM EDT - 4 months ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 22, 2025, 7:33 PM EDT - 4 months ago

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 4:05 PM EDT - 4 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 7:05 AM EDT - 4 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 15, 2025, 4:05 PM EDT - 5 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 4, 2025, 9:44 AM EDT - 5 months ago

Viking Therapeutics: A Speculative Buy

Sep 28, 2025, 2:00 PM EDT - 5 months ago

Viking Therapeutics: Overdue For Gains

Sep 23, 2025, 1:53 PM EDT - 5 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 22, 2025, 1:55 PM EDT - 5 months ago

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Sep 8, 2025, 5:43 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 23, 2025, 6:57 AM EDT - 6 months ago

Viking: Still On Track, But The Compass Needs Recalibration

Aug 20, 2025, 8:52 PM EDT - 7 months ago

Viking Therapeutics: Panic Creates Opportunity

Aug 20, 2025, 9:50 AM EDT - 7 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 19, 2025, 9:38 PM EDT - 7 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 6:27 PM EDT - 7 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 2:44 PM EDT - 7 months ago

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Aug 19, 2025, 1:45 PM EDT - 7 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 12:19 PM EDT - 7 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:05 PM EDT - 7 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Aug 19, 2025, 12:03 PM EDT - 7 months ago

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

justaguy2u Mar. 7 at 8:07 AM

$VKTX Moscow in flames, missiles headed toward New York, film at 11. Stock is up, who cares.

0 · Reply

ProfessionalIntellige Mar. 7 at 4:46 AM

$VKTX biotech developments gaining attention

0 · Reply

chuckieclam Mar. 7 at 2:27 AM

1 · Reply

biolover Mar. 7 at 2:09 AM

$VKTX nothing surprising and irrelevant. Two failed companies.

2 · Reply

longshort00 Mar. 7 at 1:57 AM

$VKTX

1 · Reply

bavariaron Mar. 7 at 1:55 AM

0 · Reply

8BALLIAM Mar. 7 at 1:22 AM

$VKTX shorts will attack on Monday Novo removed as potential buyer so.. fml

4 · Reply

Mjstockwit Mar. 7 at 1:14 AM

$VKTX soooooo also do the Feds just drop the investigation into the compounders now and false claims?

0 · Reply

Mjstockwit Mar. 7 at 1:08 AM

$VKTX NVO running scared - they could’ve owned HIMS through the lawsuit but they panicked! Why?

1 · Reply

ElonMusk101 Mar. 7 at 12:47 AM

$HIMS $NVO $SRPT $VKTX all on the move!!! Own all 4!!! Wow!! LFG!!

0 · Reply

JohnnyVacs Mar. 7 at 12:43 AM

$VKTX 40% jump on HIMS now. Wow! Our day will come.

1 · Reply

Hiphopgiraffi2 Mar. 7 at 12:41 AM

$VKTX 🙏🙏🙏

0 · Reply

JohnnyVacs Mar. 7 at 12:37 AM

$VKTX Apparently HIMS & NVO agree to sell weightloss pills together. Take a look at HIMS right now. Up 25%

0 · Reply

SauceMan912 Mar. 7 at 12:36 AM

$VKTX Hims and Novo deal back on. Hims is rocketing AH. How do we feel about the news??

3 · Reply

Stockman824 Mar. 7 at 12:20 AM

$VKTX simply put BIC

0 · Reply

Alligator Mar. 7 at 12:14 AM

$VKTX have a good weekend. Still

0 · Reply

KetCopyPaste Mar. 6 at 11:51 PM

$VKTX should be good as long as the nukes don’t drop.

0 · Reply

Tigeroflebanon Mar. 6 at 11:21 PM

$VKTX how’s that next gen product search working out for Big Pharma? …

1 · Reply

bavariaron Mar. 6 at 10:55 PM

$VKTX ** Big Pharma Ranked by Drug Sales ** Courtesy @DrSamuelBHume on X Eli Lilly is top — 60% of it is Tirzepatide! (Mounjaro + Zepbound) at $35.1B VKTX Long-Term

0 · Reply

KetCopyPaste Mar. 6 at 10:50 PM

$VKTX break 33.50 AH/PM we go full send into Monday

0 · Reply

KetCopyPaste Mar. 6 at 10:47 PM

$VKTX after all the long months here, years for some… I think I’ll sleep the best I have in a while this weekend. Enjoy it yall!

1 · Reply

RunGal Mar. 6 at 10:34 PM

$VKTX Just now on CNBC… we got singled out in Pharma discussion as being strong today on a week day…

2 · Reply

Market Cap	3.64B
Revenue (ttm)	0.00
Net Income (ttm)	-359.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,968,500
Avg Vol	3,076,172
Day's Range	N/A - N/A
Shares Out	115.55M
Stochastic %K	64%
Beta	0.75
Analysts	Strong Sell
Price Target	$92.56